Caribou Biosciences (NASDAQ:CRBU) Releases Quarterly Earnings Results, Beats Expectations By $0.05 EPS

Caribou Biosciences (NASDAQ:CRBU) posted its quarterly earnings results on Thursday. The company reported ($0.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.05, FiscalAI reports. The firm had revenue of $3.94 million for the quarter, compared to the consensus estimate of $1.96 million. Caribou Biosciences had a negative return on equity of 69.85% and a negative net margin of 1,690.45%.

Caribou Biosciences Stock Down 5.0%

Shares of Caribou Biosciences stock traded down $0.09 on Thursday, hitting $1.71. The company’s stock had a trading volume of 1,078,171 shares, compared to its average volume of 1,266,392. The company has a market capitalization of $159.83 million, a P/E ratio of -1.01 and a beta of 2.54. Caribou Biosciences has a 52-week low of $0.66 and a 52-week high of $3.54. The firm has a fifty day moving average price of $1.64 and a 200-day moving average price of $1.90.

Institutional Trading of Caribou Biosciences

Institutional investors and hedge funds have recently modified their holdings of the business. Invesco Ltd. increased its stake in shares of Caribou Biosciences by 187.2% during the 4th quarter. Invesco Ltd. now owns 35,063 shares of the company’s stock worth $56,000 after purchasing an additional 22,856 shares in the last quarter. Quadrature Capital Ltd acquired a new stake in Caribou Biosciences during the 4th quarter valued at $253,000. Man Group plc acquired a new stake in Caribou Biosciences during the 4th quarter valued at $58,000. Russell Investments Group Ltd. increased its position in Caribou Biosciences by 80.0% during the fourth quarter. Russell Investments Group Ltd. now owns 24,347 shares of the company’s stock worth $39,000 after buying an additional 10,824 shares in the last quarter. Finally, ExodusPoint Capital Management LP acquired a new position in shares of Caribou Biosciences in the fourth quarter worth $124,000. Hedge funds and other institutional investors own 77.51% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have commented on CRBU. Weiss Ratings restated a “sell (d-)” rating on shares of Caribou Biosciences in a research report on Wednesday, January 21st. HC Wainwright raised their price objective on shares of Caribou Biosciences from $3.00 to $9.00 and gave the company a “buy” rating in a research note on Wednesday, November 5th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Caribou Biosciences currently has an average rating of “Hold” and a consensus target price of $8.00.

About Caribou Biosciences

Caribou Biosciences, Inc is a clinical-stage biopharmaceutical company that leverages its proprietary CRISPR-Cas gene-editing platform to develop transformative cell therapies and in vivo treatments for a range of cancers and genetic diseases. The company’s core technology enables precise modification of cellular genomes, allowing the design of engineered T-cell and NK-cell therapies aimed at improving safety, efficacy and persistence in patients with hematologic and solid tumor malignancies. Alongside its oncology portfolio, Caribou is advancing in vivo editing programs targeting monogenic disorders, with initiatives in areas such as Duchenne muscular dystrophy and familial amyloidosis.

Established in 2011 and headquartered in Berkeley, California, Caribou Biosciences was co-founded by Nobel laureate Jennifer Doudna, one of the pioneers of CRISPR gene-editing technology.